Cassava Sciences (SAVA)

Executive Summary

Cassava Sciences is a clinical-stage biotechnology company focused on Alzheimer's disease therapeutics and diagnostics. Its lead candidate, simufilam, targets filamin A protein to reduce neuroinflammation. However, the pipeline reveals significant setbacks: two Phase 3 trials (NCT05026177, NCT05575076) have been terminated, and a third Phase 3 (NCT04994483) was completed in October 2024 with no public data yet. The company also has an investigational blood-based diagnostic, SavaDx. Given the terminated trials and lack of clarity on efficacy, the near-term outlook is highly uncertain. The company's market cap (~$84M) reflects investor skepticism. Key upcoming events include potential disclosure of Phase 3 data from the completed trial, regulatory interactions regarding the failed studies, and progress on the diagnostic program. Without positive data, the stock faces significant downside risk.

Upcoming Catalysts (preview)

• TBDPresentation of Phase 3 simufilam efficacy data from completed trial NCT0499448320% success
• Q3 2026FDA guidance or clinical hold update after terminated Phase 3 trials25% success
• TBDSavaDx diagnostic biomarker validation or regulatory submission announcement30% success